Abstract:<section class="article-section__content"><p>Glycogen storage disease type Ia (GSD Ia) is an inborn error of metabolism caused by defective glucose‐6‐phosphatase (G6PC) activity. GSD Ia patients exhibit severe hepatomegaly due to glycogen and triglyceride (TG) accumulation in the liver. We have previously shown that the activity of Carbohydrate Response Element Binding Protein (ChREBP), a key regulator of glycolysis and <i>de novo</i> lipogenesis, is increased in GSD Ia. In the current study we assessed the contribution of ChREBP to non‐alcoholic fatty liver disease (NAFLD) development in a mouse model for hepatic GSD Ia. Liver‐specific <i>G6pc</i> knockout (L‐<i>G6pc<sup>‐/‐</sup></i>) mice were treated with AAV2/8‐shChREBP to normalize hepatic ChREBP activity to levels observed in wildtype (L‐<i>G6pc<sup>+/+</sup></i>) mice receiving AAV8‐shScramble. Hepatic ChREBP knockdown markedly increased liver weight and hepatocyte size in L‐<i>G6pc<sup>‐/‐</sup></i> mice. This was associated with hepatic accumulation of G6P, glycogen and lipids, while the expression of glycolytic and lipogenic genes was reduced. Enzyme activities, flux measurements, hepatic metabolite analysis and VLDL‐TG secretion assays revealed that hepatic ChREBP knockdown reduced downstream glycolysis and <i>de novo</i> lipogenesis, but also strongly suppressed hepatic VLDL lipidation hence promoting the storage of 'old fat'. Interestingly, enhanced VLDL‐TG secretion in shScramble‐treated L‐<i>G6pc<sup>‐/‐</sup></i> mice associated with a ChREBP‐dependent induction of the VLDL lipidation proteins MTTP and TM6SF2, the latter being confirmed by ChIP‐PCR. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusion</h3><p>Attenuation of hepatic ChREBP induction in GSD Ia liver aggravates hepatomegaly due to further accumulation of glycogen and lipids as a result of reduced glycolysis and suppressed VLDL‐TG secretion. TM6SF2, critical for VLDL formation, was identified as a novel ChREBP target in mouse liver. Altogether, our data show that enhanced ChREBP activity limits NAFLD development in GSD Ia by balancing hepatic TG production and ‐secretion.</p></section>

Modeling Phenotypic Heterogeneity of Glycogen Storage Disease Type 1a Liver Disease in Mice by Somatic CRISPR/CRISPR‐associated protein 9–Mediated Gene Editing

Pathological modeling of glycogen storage disease type III with CRISPR/Cas9 edited human pluripotent stem cells

Hepatic Carbohydrate Response Element Binding Protein Activation Limits Nonalcoholic Fatty Liver Disease Development in a Mouse Model for Glycogen Storage Disease Type 1a

Characterization of liver GSD IX γ2 pathophysiology in a novel Phkg2-/- mouse model

Disease-associated programming of cell memory in glycogen storage disorder type 1a

Genome editing using Staphylococcus aureus Cas9 in a canine model of glycogen storage disease Ia

Induced pluripotent stem cell (iPSC) modeling validates reduced GBE1 enzyme activity due to a novel variant, p.Ile694Asn, found in a patient with suspected glycogen storage disease IV

Molecular biology and gene therapy for glycogen storage disease type Ib

Normalization of hepatic ChREBP activity does not protect against liver disease progression in a mouse model for Glycogen Storage Disease type Ia

mRNA therapy restores euglycemia and prevents liver tumors in murine model of glycogen storage disease

Natural history study of hepatic glycogen storage disease type IV and comparison to Gbe1ys/ys model

A liver‐humanized mouse model of carbamoyl phosphate synthetase 1‐deficiency

Molecular mechanisms of catalytic inhibition for active site mutations in glucose-6-phosphatase catalytic subunit 1 linked to glycogen storage disease

Clinical and biochemical heterogeneity between patients with glycogen storage disease type IA: the added value of CUSUM for metabolic control

A splice-switching oligonucleotide treatment ameliorates glycogen storage disease type 1a in mice with G6PC c.648G>T

Base editing of the GLB1 gene is therapeutic in GM1 gangliosidosis patient-derived cells

Liver Glycogen Phosphorylase Deficiency Leads to Profibrogenic Phenotype in a Murine Model of Glycogen Storage Disease Type VI

Gene Therapy for Glycogen Storage Diseases

An evolutionary approach to optimizing glucose-6-phosphatase-α enzymatic activity for gene therapy of glycogen storage disease type Ia

In vivo dissection of the mouse tyrosine catabolic pathway with CRISPR-Cas9 identifies modifier genes affecting hereditary tyrosinemia type 1

Reprogramming Metabolic Pathways in Vivo with CRISPR/Cas9 Genome Editing to Treat Hereditary Tyrosinaemia